<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005812</url>
  </required_header>
  <id_info>
    <org_study_id>D9812</org_study_id>
    <secondary_id>DMS-9812</secondary_id>
    <secondary_id>NCI-G00-1782</secondary_id>
    <nct_id>NCT00005812</nct_id>
  </id_info>
  <brief_title>Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma</brief_title>
  <official_title>A Pilot Phase II Trial of Temozolomide in Leptomeningeal Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who&#xD;
      have leptomeningeal metastases from a solid tumor or lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate, survival time, and quality of life of patients&#xD;
           with leptomeningeal metastases from a solid tumor or lymphoma when treated with oral&#xD;
           temozolomide.&#xD;
&#xD;
        -  Determine adverse events related to this regimen in this patient population.&#xD;
&#xD;
        -  Measure temozolomide concentrations in CSF and serum and correlate with appropriate&#xD;
           pharmacodynamic parameters (e.g., response) in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive oral temozolomide daily for 6 weeks. Courses repeat every 10 weeks&#xD;
      in the absence of unacceptable toxicity or disease progression.&#xD;
&#xD;
      Patients with a complete response (CR) receive 2 additional courses after achieving CR.&#xD;
      Patients with a CR except for residual radiographic abnormalities that persist unchanged for&#xD;
      2 full courses continue for 4 courses past best response.&#xD;
&#xD;
      Quality of life is assessed at baseline, weekly for the first 4 weeks of therapy, and then&#xD;
      monthly thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No objective response documented, protocol terminated after 12 patients.&#xD;
  </why_stopped>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response</measure>
    <time_frame>Every 6 weeks</time_frame>
    <description>Response will be assessed clinically, cytologically, and radiographically.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Every 6 weeks</time_frame>
    <description>Drug levels in cerebrospinal fluid assessed every 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>every 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Baseline, weekly during cycle 1, before each additional cycle</time_frame>
    <description>FACT-Br</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Brain Tumors</condition>
  <condition>Central Nervous System Tumors</condition>
  <condition>Leptomeningeal Metastases</condition>
  <arm_group>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral temozolomide 75 mg/m2/day for 6 weeks, followed by 4 week break. Cycles will continue until:&#xD;
disease progression&#xD;
intolerable toxicity&#xD;
complete response - 2 full additional cycles&#xD;
if response is complete except for residual radiographic abnormalities that persist unchanged for 2 full cycles: continue for 4 cycles past best response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <arm_group_label>Temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Documented leptomeningeal metastases&#xD;
&#xD;
          -  Carcinomatous meningitis that is previously untreated or failed prior therapy OR&#xD;
&#xD;
          -  Lymphomatous meningitis&#xD;
&#xD;
          -  Systemic disease that is responding or stable on current therapy not eligible if&#xD;
             discontinuing therapy would be deleterious&#xD;
&#xD;
          -  Age 18 and over&#xD;
&#xD;
          -  Karnofsky Performance Status 60-100%&#xD;
&#xD;
          -  Life expectancy of at least 6 weeks&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/μL&#xD;
&#xD;
          -  Platelet count greater than 100,000/μL&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No contraindication to diagnostic sampling of CSF via lumbar puncture or reservoir&#xD;
&#xD;
          -  No medical conditions that would interfere with absorption of oral medication (e.g.,&#xD;
             malabsorption, obstruction, or frequent vomiting)&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  Prior neuroaxis chemotherapy (lumbar puncture, reservoir, or systemic) allowed&#xD;
&#xD;
          -  No other concurrent chemotherapy for other sites of disease&#xD;
&#xD;
          -  No prior radiotherapy to areas of measurable meningeal disease unless there is clear&#xD;
             radiographic progression in these areas&#xD;
&#xD;
          -  No prior radiotherapy to greater than 30% of bone marrow&#xD;
&#xD;
          -  Prior radiotherapy to the neuroaxis allowed&#xD;
&#xD;
          -  No concurrent radiotherapy for other sites of disease or for progressive disease&#xD;
&#xD;
          -  Recovered from any prior recent therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas H. Davis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Davis TH, Fadul CE, Glantz MJ, et al.: Pilot phase II trial of temozolomide for leptomeningeal metastases: preliminary report. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-460, 2003. ISBN 1932312021</citation>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 13, 2013</last_update_submitted>
  <last_update_submitted_qc>May 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leptomeningeal metastases</keyword>
  <keyword>temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

